Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma

NCT02811783 is registered in ClinicalTrials.gov with Elorac, Inc. as lead sponsor.

NCT NCT02811783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02811783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Lead sponsor
Elorac, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2017
Completion date
September 30, 2022
Enrollment
59 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, t-cell, cutaneous, mycosis fungoides, sézary syndrome